Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Expert Rev Mol Diagn. 2022 Feb;22(2):223-231. doi: 10.1080/14737159.2022.2019015. Epub 2021 Dec 30.
Signal sequence receptor subunit delta (SSR4) gene is reported to encode the translocon-associated protein δ and related with the human immune regulation. However, the expression of SSR4 in colon adenocarcinoma (COAD) and its correlation with clinical treatment remains unclear.
SSR4 mRNA expression level and its relationship with tumor infiltrating lymphocytes (TILs) in COAD were evaluated through several databases. Furthermore, the study collected 238 cases of COAD tissue samples to detect the association of SSR4 protein expression level in TILs with clinical pathological information, and the prognosis of COAD.
SSR4 mRNA was significantly highly expressed in COAD tissues and significantly correlated with several types of TILs in COAD. Moreover, SSR4 highly expressed in many types of TILs, especially highly expressed in plasma cell from COAD patients with advanced TNM stage. High SSR4 protein expression in TILs was associated with lymph node metastasis, distant metastasis, American Joint Committee on Cancer (AJCC) staging, and Response Evaluation Criteria in Solid Tumors (RECIST) efficacy. COAD patients with high SSR4 expression in TILs had better overall survival.
In conclusion, high SSR4 mRNA and protein expression in TILs can be used as a prognostic biomarker for predicting better overall survival and treatment efficacy in COAD patients.
信号序列受体亚单位 delta（SSR4）基因被报道编码易位子相关蛋白 δ，并与人类免疫调节有关。然而，SSR4 在结肠腺癌（COAD）中的表达及其与临床治疗的相关性尚不清楚。
通过多个数据库评估 SSR4 mRNA 表达水平及其与 COAD 中肿瘤浸润淋巴细胞（TILs）的关系。此外，本研究收集了 238 例 COAD 组织样本，以检测 TILs 中 SSR4 蛋白表达水平与临床病理信息和 COAD 预后的相关性。
SSR4 mRNA 在 COAD 组织中显著高表达，与 COAD 中的几种类型的 TILs 显著相关。此外，SSR4 在 COAD 患者的多种类型的 TILs 中高表达，尤其是在晚期 TNM 分期的 COAD 患者的浆细胞中高表达。TILs 中 SSR4 蛋白高表达与淋巴结转移、远处转移、美国癌症联合委员会（AJCC）分期和实体瘤反应评估标准（RECIST）疗效有关。TILs 中 SSR4 高表达的 COAD 患者总生存率更好。
总之，TILs 中高 SSR4 mRNA 和蛋白表达可用作预测 COAD 患者总生存率和治疗疗效更好的预后生物标志物。
